| Q31155650 | A bioplex analysis of cytokines and chemokines in first trimester maternal plasma to screen for predictors of miscarriage |
| Q36070442 | A comparison of sample collection methods for quantifying cell-free fetal neurodevelopment transcripts in amniotic fluid |
| Q64092098 | A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 Trial): study protocol |
| Q54232440 | A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin. |
| Q39250424 | ATF3 is a negative regulator of inflammation in human fetal membranes |
| Q36112242 | Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening. |
| Q50026911 | Accurately predicting the risk of serious maternal morbidity in preterm preeclampsia: Can It be done? |
| Q47673554 | Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta. |
| Q83200755 | Activin A, hypoxia and the prediction of obstetric outcomes |
| Q90623935 | Acupuncture in pregnancy; primum non nocere |
| Q58782105 | Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study |
| Q61989069 | Association Between Twin Discordance at 6–9 Weeks' of Gestation and Birthweight Complications |
| Q61842549 | Association between low day 16 hCG and miscarriage after proven cardiac activity |
| Q83365229 | Association between maternal serum cytokine profiles at 7-10 weeks' gestation and birthweight in small for gestational age infants |
| Q91829102 | Blood-based biomarkers in the maternal circulation associated with fetal growth restriction |
| Q54263680 | Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin. |
| Q39695246 | Characterization of symptoms immediately preceding eclampsia |
| Q36047180 | Chorioamnionitis Occurring in Women With Preterm Rupture of the Fetal Membranes Is Associated With a Dynamic Increase in mRNAs Coding Cytokines in the Maternal Circulation |
| Q61446626 | Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin |
| Q35054999 | Circulating MicroRNAs in maternal blood as potential biomarkers for fetal hypoxia in-utero |
| Q43816234 | Circulating RNA coding genes regulating apoptosis in maternal blood in severe early onset fetal growth restriction and pre-eclampsia. |
| Q91768143 | Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia |
| Q45215554 | Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy |
| Q33762029 | Combination gefitinib and methotrexate treatment for non-tubal ectopic pregnancies: a case series |
| Q91785097 | Combination methotrexate and gefitinib: A potential medical treatment for inoperable nontubal ectopic pregnancy |
| Q50343421 | Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia. |
| Q61847059 | Cord blood sampling at delivery: do we need to always collect from both vessels? |
| Q50758029 | Corin, an enzyme with a putative role in spiral artery remodeling, is up-regulated in late secretory endometrium and first trimester decidua. |
| Q47255449 | Corpus luteum across the first trimester: size and laterality as observed by ultrasound |
| Q90346161 | Death associated protein kinase 1 (DAPK-1) is increased in preeclampsia |
| Q61846984 | Decline in βhCG levels between days 0 and 4 after a single dose of methotrexate for ectopic pregnancy predicts treatment success: a retrospective cohort study |
| Q76360960 | Determining zygosity in early pregnancy by ultrasound |
| Q61413199 | Diagnostic Accuracy of Maternal Serum Macrophage Inhibitory Cytokine-1 and Pregnancy-Associated Plasma Protein-A at 6–10 Weeks of Gestation to Predict Miscarriage |
| Q90344849 | Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome |
| Q41725684 | Dizygotic twinning as a measure of human fertility |
| Q36258825 | Double blind, randomised, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE Trial): a study protocol |
| Q90344835 | EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia |
| Q57282918 | ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia |
| Q91274193 | Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia |
| Q38407123 | Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia |
| Q39089196 | Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth |
| Q34872541 | Effects of maternal obstructive sleep apnoea on fetal growth: a prospective cohort study. |
| Q36024649 | Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta |
| Q52677037 | Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro. |
| Q90585427 | Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial |
| Q34395372 | Evaluation of ADAM-12 as a diagnostic biomarker of ectopic pregnancy in women with a pregnancy of unknown location. |
| Q46309172 | Expectant management of severe preterm preeclampsia: a comparison of maternal and fetal indications for delivery. |
| Q44791649 | Fetal activin A: associations with labour, umbilical artery pH and neonatal outcome |
| Q44818655 | First trimester levels of inhibins and activin A in normal and failing pregnancies |
| Q39024459 | Galectin-7 acts as an adhesion molecule during implantation and increased expression is associated with miscarriage. |
| Q61639330 | Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000-10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial |
| Q34416727 | Has increased clinical experience with methotrexate reduced the direct costs of medical management of ectopic pregnancy compared to surgery? |
| Q53790457 | Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. |
| Q47254611 | High-dose compared with low-dose oxytocin for induction of labour of nulliparous women at term. |
| Q61847011 | Highly specific and sensitive rise in Days 14–17 pro-αC inhibin with clinical pregnancy after frozen embryo transfer with ovulatory cycles |
| Q40970908 | Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction |
| Q44724176 | Hysteroscopy under general anaesthesia, a near painless procedure |
| Q39994319 | Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeks' gestation. |
| Q36048062 | Impairment of Angiogenic Sphingosine Kinase-1/Sphingosine-1-Phosphate Receptors Pathway in Preeclampsia. |
| Q45050603 | Increased day 15-17 serum pro-alphaC inhibin levels specific to successful pregnancy |
| Q35064307 | Inhibins and activins: clinical advances in reproductive medicine |
| Q34064856 | Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study |
| Q55031559 | Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production. |
| Q51099406 | Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction. |
| Q53810474 | Loss of Akt increases soluble endoglin release from endothelial cells but not placenta. |
| Q40469578 | Low levels of pregnancy-associated plasma protein-A in asymptomatic women destined for miscarriage. |
| Q44454381 | MHR welcomes high-quality basic reproductive research around pregnancy. |
| Q53188450 | MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. |
| Q28480929 | MMP-15 is upregulated in preeclampsia, but does not cleave endoglin to produce soluble endoglin |
| Q46831063 | MT-MMPs in pre-eclamptic placenta: relationship to soluble endoglin production |
| Q42039010 | Maternal and foetal activin A levels: associations with normal and abnormal labour |
| Q44100597 | Maternal and foetal activin A levels: associations with normal and abnormal labour |
| Q90071446 | Maternal mortality at the National Referral Hospital in Honiara, Solomon Islands over a five-year period |
| Q54197987 | Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia. |
| Q61847032 | Maternal serum activin A and the prediction of intrauterine growth restriction |
| Q47838589 | Maternal serum and amniotic fluid levels of macrophage inhibitory cytokine 1 in Down syndrome and chromosomally normal pregnancies |
| Q53103358 | Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage. |
| Q61989066 | Measurement of mRNA Transcripts of Very High Placental Expression in Maternal Blood as Biomarkers of Preeclampsia |
| Q38973677 | Measuring circulating placental RNAs to non-invasively assess the placental transcriptome and to predict pregnancy complications. |
| Q38208033 | Measuring hypoxia-induced RNA in maternal blood: a new way to identify critically hypoxic fetuses in utero? |
| Q36849333 | Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study. |
| Q54116564 | Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia. |
| Q53343144 | Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. |
| Q61413210 | Miscarriage Risk for Asymptomatic Women After a Normal First-Trimester Prenatal Visit |
| Q38251364 | Molecular diagnostics and therapeutics for ectopic pregnancy. |
| Q51312698 | Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta. |
| Q39695235 | Of leaves and butterflies: how methotrexate came to be the savior of women |
| Q39181828 | PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia |
| Q39212128 | PLAC4 is upregulated in severe early onset preeclampsia and upregulated with syncytialisation but not hypoxia |
| Q112566864 | PSG7 and 9 (Pregnancy-Specific β-1 Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia |
| Q51050676 | Paternal obesity in a rodent model affects placental gene expression in a sex-specific manner. |
| Q52935430 | Peptides do not prevent cleavage of endoglin to produce soluble endoglin. |
| Q37029975 | Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol |
| Q39636183 | Placental HtrA3 is regulated by oxygen tension and serum levels are altered during early pregnancy in women destined to develop preeclampsia |
| Q35885014 | Placental Insufficiency in Fetuses That Slow in Growth but Are Born Appropriate for Gestational Age: A Prospective Longitudinal Study |
| Q86123507 | Placental SEMA3B expression is not altered in severe early onset preeclampsia |
| Q54589324 | Placental expression of a novel primate-specific splice variant of sFlt-1 is upregulated in pregnancies complicated by severe early onset pre-eclampsia. |
| Q46321132 | Placental specific mRNA in the maternal circulation are globally dysregulated in pregnancies complicated by fetal growth restriction |
| Q38958877 | Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity. |
| Q46305857 | Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis |
| Q34998473 | Plasma MIC-1 and PAPP-a levels are decreased among women presenting to an early pregnancy assessment unit, have fetal viability confirmed but later miscarry |
| Q46081772 | Predicting perinatal outcome through changes in umbilical artery Doppler studies after antenatal corticosteroids in the growth-restricted fetus |
| Q90221067 | Prediction of adverse maternal outcomes in preeclampsia at term |
| Q90017779 | Predictive Value of the Signs and Symptoms Preceding Eclampsia: A Systematic Review |
| Q89918720 | Preventing preeclampsia with aspirin: does dose or timing matter? |
| Q61846959 | Prognostic value of human chorionic gonadotropin levels 4 days after a single dose of methotrexate for ectopic pregnancy |
| Q51172859 | Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction. |
| Q92079956 | Proton Pump Inhibitors and Preeclampsia Risk Among 157 720 Women |
| Q33643447 | Quantifying circulating hypoxia-induced RNA transcripts in maternal blood to determine in utero fetal hypoxic status |
| Q44778018 | Quantifying mRNA coding growth genes in the maternal circulation to detect fetal growth restriction |
| Q33822185 | Rational design of immunostimulatory siRNAs. |
| Q41571601 | Reduced growth velocity across the third trimester is associated with placental insufficiency in fetuses born at a normal birthweight: a prospective cohort study. |
| Q33687481 | Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment. |
| Q90166528 | Screening circulating proteins to identify biomarkers of fetal macrosomia |
| Q61843304 | Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage |
| Q34184588 | Serum concentrations of soluble Flt-1 are decreased among women with a viable fetus and no symptoms of miscarriage destined for pregnancy loss |
| Q35071433 | Severe early-onset preeclampsia is not associated with a change in placental catechol O-methyltransferase (COMT) expression. |
| Q54291529 | Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia. |
| Q38973642 | Soluble endoglin production is upregulated by oxysterols but not quenched by pravastatin in primary placental and endothelial cells |
| Q43805959 | Sonography: dizygotic twin survival in early pregnancy |
| Q40239467 | Stability of absolute copy number of housekeeping genes in preeclamptic and normal placentas, as measured by digital PCR. |
| Q39167263 | Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia |
| Q90331732 | Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling |
| Q64099971 | Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction |
| Q90103423 | Systematic review of areca (betel nut) use and adverse pregnancy outcomes |
| Q46867714 | Targeted nanoparticle delivery of doxorubicin into placental tissues to treat ectopic pregnancies. |
| Q58604153 | The cerebral-placental-uterine ratio as a novel predictor of late fetal growth restriction: a prospective cohort study |
| Q33597590 | The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer |
| Q35825304 | The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review. |
| Q39090468 | The role of leukemia inhibitory factor in tubal ectopic pregnancy. |
| Q91465996 | The untapped potential of placenta-enriched molecules for diagnostic and therapeutic development |
| Q36932908 | The use of miRNA microarrays for the analysis of cancer samples with global miRNA decrease |
| Q45987940 | Thyroid function and autoantibody status among women who spontaneously deliver under 35 weeks of gestation. |
| Q40767462 | Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14. |
| Q46313212 | Treatment of early-onset preeclampsia with continuous positive airway pressure |
| Q60640533 | Two Corpora Lutea Seen at 6–13 Weeks' Gestation Infers Dizygosity Among Spontaneous Same-Sexed Dichorionic Twins |
| Q40900370 | Use of dizygotic to monozygotic twinning ratio as a measure of fertility |
| Q34569880 | Using a decline in serum hCG between days 0-4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study. |
| Q51285963 | Variable effect of maternal oral glucose load on circulating cell-free placental mRNAs. |
| Q50074983 | Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. |
| Q53433407 | YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. |
| Q47447019 | sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies? |